- Loading: 10–20 mg intravenous (IV) up to 100 mg/day [23]

- Maintenance: 4–8 mg/day (mild symptoms) to 16 mg/day (moderate to severely symptomatic); up to 24 mg/day [23, 44]

- Long half-life (3–4 h with biologic half-life 34–54 h) [45]

- Low/absent mineralocorticoid activity, less psychosis, improvement in clinical condition pre-operatively, lower infection risk [23]

- Increased risk of myopathy [23]

- May alter the appearance of post-contrast imaging [45]

- Decreased survival among GBM patients undergoing radiation [45]

- Decreased half-life in the setting of co-administration of phenytoin [47]

- 5–60 mg/day [49]

- Lower risk of myopathy [23]

- Allows smaller dose taper for those with adrenal insufficiency history

- Less mineralocorticoid potency that hydrocortisone [49]

- Less efficacious for brain edema [23]

- 20–30 mg/day [49]

- Lower risk of myopathy [23, 49]

- Increased mineralocorticoid potency compared to dexamethasone [49]

- Shorter biological half-life (8–12 h)